NCT02596880View on ClinicalTrials.gov

Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2016

Conditions
Hepatitis CCirrhosis
Interventions
DRUG

Sofosbuvir

400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir

DRUG

Daclatasvir

60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir

DRUG

Ribavirin

1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses

Trial Locations (1)

14117

Shariati Hospital, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT02596880 - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics | Biotech Hunter | Biotech Hunter